Pharma BD Deal Intelligence
King Pharmaceuticals Inc. / Aventis Pharmaceuticals (Intal/Tilade/Synercid rights)
2002 · Licensing/Option · $275M · Complete
Announcement Sentiment
50
Neutral / mixed
December 30, 2002 acquisition of US rights to Intal (cromolyn), Tilade (nedocromil) and Synercid (quinupristin/dalfopristin) plus associated IP.
Key facts
- Announced Dec 30, 2002
- Closed Dec 30, 2002
- Deal value $275M
- Deal type Licensing/Option
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals